Cancers, Volume 12, Issue 1 (January 2020) – 254 articles
Cover Story (view full-size image):
The introduction of immunotherapy marks a step forward in the quest for a cure for multiple myeloma. Monoclonal antibodies that target CD38 (daratumumab) and CS1 (elotuzumab) are highly effective and safe options for young and elderly patients. Daratumumab has been included in many regimens and moved from the relapsed to the frontline setting. Furthermore, antibody-drug conjugates such as belantamab mafodotin (GSK2857916) are also under clinical evaluation. Active immunotherapy, aimed at awakening patients’ immune systems against myeloma cells, is of great interest, with bispecific T cell engagers such as AMG420 proving to be effective in heavily pretreated patients in clinical trials. A number of challenges still remain, including the following: finding the correct timing for these agents during the disease course, understanding the mechanisms of resistance, and identifying the
[...] Read more.
- Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
- You may sign up for e-mail alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader
to open them.
Previous Issue
Next Issue